Inadequate growth hormone suppression following an octreotide test dose predicts the need for adjuvant therapy to achieve 'safe' growth hormone levels

Clin Endocrinol (Oxf). 2006 Apr;64(4):475-6. doi: 10.1111/j.1365-2265.2006.02480.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Acromegaly / blood*
  • Chemotherapy, Adjuvant
  • Growth Hormone / blood*
  • Humans
  • Octreotide*
  • Patient Selection

Substances

  • Growth Hormone
  • Octreotide